The DOI matches its Crossref record.
P-285 Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connectmultiple myeloma disease registry
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with triple-class-exposed relapsed and refractory multiple myeloma, conventional therapies yield poor prognosis, with median progression-free survival of approximately 3 to 5 months and median overall survival of approximately 9 to 22 months.
“Prognosis is poor with conventional therapies, with a median progression-free survival (PFS) of ~3 to 5 months and a median overall survival (OS) of ~9 to 22 months in this patient population. 5-12”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [10]
Citations
Cited by
Sorted by citations
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood · doi:10.1182/blood.2024024582 · Cited by 79
Self-citation
Metadata
- Authors
- Lee, H., Ailawadhi, S., Dhanda, D., Patwardhan, P., Yu, E., Liu, L., Rifkin, R., Terebelo, H., Abonour, R., Narang, M., Gasparetto, C., Toomey, K., Hardin, J., Durie, B., & Jagannath, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic in Florida (US)
- Bristol-Myers Squibb (United States) (US)
- Rocky Mountain Cancer Centers (US)
- Ascension Providence Hospital (US)
- Indiana University School of Medicine (US)
- Maryland Oncology Hematology (US)
- Duke University (US)
- University of South Carolina (US)
- Cedars-Sinai Medical Center (US)
- ORCID
- Venue
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 23
- Pages
- S193-S194
- ISSN
- 2152-2650 (ISSN-L)
- OpenAlex
- W4387003691
- Cited by
- 1
- References
- 0
- Citations by year
- 2024: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Clinical Lymphoma Myeloma & Leukemia (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- relapsed/refractory multiple myeloma, carfilzomib, lenalidomide, dexamethasone, proteasome inhibitors, treatment patterns, real-world outcomes, inclusion and exclusion criteria, progression-free survival, overall survival, minimal residual disease, high-risk cytogenetics, hematologic toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
